Cell and gene therapy (CGT) is redefining treatment by offering potential solutions for cancers, rare genetic disorders, and chronic conditions. Yet, its complexity brings unique regulatory hurdles, particularly in Singapore, where safety, efficacy, and quality standards are uncompromising.

To support innovation, the Health Sciences Authority (HSA) has implemented a clear framework for cell, tissue, and gene therapy products (CTGTPs). For biotech innovators, understanding this framework is critical to securing approvals. In this guide, we break down the registration process and showcase how a regulatory affairs consultant, like The Reg Consultants (TRC), can help you get there faster and with fewer surprises.

Overview of Singapore’s Cell and Gene Therapy Regulations

Defining CTGTPs under the Health Products Act

In Singapore, cell, tissue, and gene therapy products (CTGTPs) are regulated under the Health Products Act. This classification encompasses a broad range of products, including:

• Autologous therapies (derived from a patient’s own cells)
• Allogeneic therapies (utilising donor cells)
• Genetically modified cells
• Viral vector–based therapies

Clear definitions and classifications help sponsors understand exactly where their products sit within the regulatory system.

Alignment with International Standards

Singapore also aligns its standards with international frameworks, such as:

• The Pharmaceutical Inspection Co-operation Scheme (PIC/S)
• International Council for Harmonisation (ICH)
• The European Medicines Agency (EMA)

This international alignment allows sponsors developing products across multiple jurisdictions to avoid duplicate testing and rely more effectively on global data.

Importance of Early Engagement with the HSA

Importantly, early engagement with HSA is encouraged. Pre-submission meetings allow sponsors to discuss their development programme, clarify regulatory expectations, and seek guidance on dossier preparation. For developers of cell and gene therapy pipelines in Singapore, these meetings are crucial for reducing uncertainty and improving submission readiness.

Key Regulatory Requirements for CGT Product Registration

Registering a cell and gene therapy product under the Health Products Act involves several layers of regulatory requirements. These include manufacturing, scientific evidence, and product-specific safety considerations.

1. Licensing

Developers must hold the appropriate licence under the Therapeutic Product framework, which covers the commercial supply of cell and gene therapy products in Singapore.

2. Product Registration

To register a cell and gene therapy product in Singapore, sponsors must submit a comprehensive data package covering three main areas:

• Quality: The Chemistry, Manufacturing, and Controls (CMC) section should detail process controls, stability data, validated assays, and comparability studies to demonstrate product consistency.
• Non-clinical studies: These may include biodistribution, toxicology, and other pre-clinical investigations that support safety before human use.
• Clinical evidence: Robust clinical data must confirm both safety and efficacy, with study designs appropriate to the therapy type and patient population.

3. Donor Eligibility, Sterility, and Traceability

For autologous therapies, tracking patient material from collection through administration is critical. For allogeneic therapies, donor eligibility screening, viral testing, and traceability must be fully documented. These measures ensure product safety and allow for rapid follow-up in the event of adverse events.

4. Good Manufacturing Practice (GMP)

Facilities that manufacture cell and gene therapy products must be GMP-certified. This demonstrates adherence to rigorous quality standards, minimises contamination risks, and supports product consistency across batches. While the HSA may recognise GMP certificates from trusted overseas agencies, inspections may still be required for novel manufacturing approaches.

Meeting these requirements is often complex, especially for innovative therapies that do not fit neatly into traditional pharmaceutical models. For this reason, many biotech firms seek the guidance of experienced providers of pharma regulatory services, like TRC, to navigate Singapore’s expectations efficiently.

Navigating Submission Pathways and Review Timelines

Key Takeaways

• Generic drug applications in Singapore follow a structured pathway but are prone to delays if dossiers are incomplete.
• Bioequivalence studies are often central to approval, especially when formulation differences exist.
• The ASEAN Common Technical Dossier (ACTD) format must be followed closely, with Module 3 posing the highest risk of rejection.
• Patent and exclusivity checks are vital to avoid costly disputes.
• Prompt, thorough responses to queries from the Health Sciences Authority (HSA) can significantly reduce approval timelines.

Opportunities and Risks for Generic Drug Applications in Singapore

Singapore has built a strong reputation for its efficient yet rigorous pharmaceutical regulatory system. For companies, securing approval for a generic drug application is both commercially critical and highly competitive, with delays leading to lost market share and postponed cost savings for patients.

While HSA provides clear pathways for approval, many submissions still face setbacks due to technical oversights or incomplete dossiers. In this guide, we break down the various requirements and common pitfalls, helping companies improve their chances of success.

Understanding Eligibility and Data Requirements

To be approved in Singapore, a generic product must be pharmaceutically equivalent to an already registered reference drug. This includes using the same active ingredients, dosage form, strength, and route of administration.

Bioequivalence studies are a key requirement, demonstrating that the generic product behaves in the body in the same manner as the reference drug. In practice, this means the active ingredient must be absorbed at a similar rate and reach comparable levels in the bloodstream. 

For example, some modified-release tablets have produced inconsistent absorption patterns in studies, prompting HSA to request additional supporting data before approval. As such, companies will need to ensure thorough planning of study design, population, and analytical methods before initiating an application.

What are the Submission Format and Modules?

Applications must follow the ICH CTD or the ACTD format and structure for generic drugs. This typically covers Modules 1 through 5:

• Module 1: Administrative and Product Information

Includes the authorisation letter, artwork, proof of approval and patent-specific information.

• Module 2: Summaries

Provides high-level overviews of quality, non-clinical, and clinical data. This section should be aligned with ICH/ASEAN CTD guidance to ensure clarity and consistency.

• Module 3: Quality (CMC)

Covers both drug substance and drug product information, including manufacturing processes, control of materials, specifications, stability data, and justification of impurity limits. This is typically the most resource-intensive section of the dossier, and deficiencies here (such as incomplete stability data or poorly justified control strategies) are among the most common reasons for HSA queries or rejection.

• Modules 4 and 5: Non-Clinical and Clinical

Presents supporting pharmacology, toxicology, and clinical data. For generic products, the clinical module typically consists mainly of a bioequivalence study report, while new drug applications or biologics will require more extensive safety and efficacy data.

Careful attention to the quality module (Module 3) and, where applicable, the clinical module (Module 5) is essential. Engaging an experienced regulatory affairs consultant ensures dossiers are complete, scientifically justified, and structured in accordance with HSA expectations, significantly reducing the risk of delays.

Key Considerations for Patents and Exclusivity

Another key step in the drug registration pathway is confirming the patent status of the reference product. Even if a generic drug meets all scientific requirements, it cannot be marketed in Singapore until the patent protection on the originator drug has expired or been legally addressed. Filing an application prematurely, without this confirmation, can result in long delays, legal disputes, or even injunctions that block market entry.

To avoid this, companies should leverage patent databases and regulatory intelligence tools to confirm expiry dates, non-infringement positions, or potential licensing opportunities. Conducting this due diligence upfront can prevent costly disputes and wasted resources.

Common Technical Errors to Avoid During Application

Even when the overall regulatory strategy is well-planned, technical deficiencies in the dossier remain one of the leading causes of delays or outright rejection. Common pitfalls include:

• Incomplete CMC documentation: E.g., missing critical details on raw material controls, manufacturing steps, or analytical method validation.
• Omission of process validation reports: HSA frequently requests clarification where commercial-scale validation data are absent or insufficient.
• Misaligned specifications: Quality specifications that do not reconcile with actual batch release results or reported stability data.
• Non-compliance with ASEAN stability requirements: Includes inadequate long-term data for Zone IVb (hot/humid conditions), or failure to justify extrapolated shelf-life claims.

These errors may appear “technical,” but they often force applicants into lengthy rounds of queries or resubmissions. At TRC, we emphasise early, detail-oriented dossier preparation aligned with HSA and ASEAN guidelines to prevent such setbacks.

Navigating Submission Queries from the HSA

Even with a well-prepared dossier, it is common for HSA to raise queries during review. These may cover:

• Bioequivalence studies: Design, subject selection, or interpretation of results.
• Manufacturing processes: Deviations during scale-up or site-specific differences.
• Analytical methods and validation: Adequacy of validation protocols or robustness of data.

At TRC, we know that how you respond matters as much as the data itself. Timely, clear, and well-justified responses keep the review moving, while vague or delayed replies almost always extend timelines.

We typically advise our clients to:

• Implement internal processes for fast access to source data and reports.
• Anticipate common areas of questioning and prepare justification packages in advance.
• Ensure responses are concise, evidence-based, and aligned with HSA’s expectations.

By planning for post-submission dialogue from the outset, companies not only avoid unnecessary delays but also build confidence with regulators. TRC supports clients in drafting and managing these responses, ensuring every communication reflects both compliance and professionalism by offering HSA registration and regulatory support. 

Partnering for Successful Generic Drug Applications in Singapore

To successfully navigate a generic drug application in Singapore, companies must prepare proactively, pay rigorous attention to dossier quality, and implement clear strategies for responding to regulatory queries. With the right expertise, you can reduce the risk of costly delays and improve your chances of first-cycle approval.

At The Reg Consultants, we provide comprehensive pharma regulatory services that guide you through every stage of the generic drug approval process. From dossier preparation to HSA submissions, our team ensures accuracy, efficiency, and full regulatory alignment. Together, we help companies achieve faster approvals and sustained market access in Singapore.

Speak with our experts today and get clear guidance for your next submission.

Key Takeaways

• The electronic Common Technical Document (eCTD) is set to become the preferred format for pharmaceutical applications in Singapore.
• Technical errors such as incorrect metadata or folder naming remain a leading cause of rejection.
• Strong infrastructure, trained staff, and lifecycle management systems are essential to success.
• Different application types (biologics, new drugs, or generics) have unique requirements.
• Early adoption of future eCTD submission standards will give companies a compliance advantage.

Navigating the Shift to eCTD Submissions in Singapore

In Singapore, the eCTD is set to become the preferred standard for regulatory submissions, covering new drug, generic, and biologics licence applications. However, the format demands precision. From incorrect folder names to metadata errors, even minor missteps in meeting eCTD validation criteria can result in rejection, delays, and costly resubmissions.

Below are the key challenges and regulatory considerations that companies must address in order to ensure successful eCTD submissions.

Understanding eCTD Format Requirements

The eCTD format is built on a modular structure (Modules 1–5), where every document must be correctly named, hyperlinked, and formatted according to the Health Sciences Authority’s (HSA) technical guidance. Since validation is automated, even small errors can result in outright rejection. 

Common mistakes include:

• Incorrect folder naming conventions (one of the leading causes of rejection)
• Broken cross-references or missing hyperlinks
• Non-compliant PDF settings

Companies must therefore adopt a detail-focused approach, using pre-validation checks before submission to ensure every sequence passes.

Infrastructure Essentials for Smooth eCTD Submissions

A strong technical foundation is essential for a successful submission. This includes the right publishing tools, secure systems, and personnel who understand both the technology and regulatory requirements.

Key elements to consider include:

• Compliant eCTD software: Use publishing and validation tools that meet international standards and validation criteria set by the HSA.
• System readiness: Ensure hardware compatibility, implement secure data storage, establish backup protocols, and maintain audit trails to protect data integrity.
• Document management systems (DMS): Integrate platforms for version control, permissions, and archiving to avoid errors and duplications.
• Trained personnel: Staff must be trained to operate publishing tools, troubleshoot validation errors, and manage sequence numbering.
  

For companies without in-house expertise, consider engaging a trusted regulatory consultancy with a strong track record in eCTD implementation and familiarity with HSA requirements. With their help, you can ensure accurate, compliant, and timely submissions.

From Approval to Updates: Managing the eCTD Lifecycle

One of the main advantages of the eCTD format is its ability to handle post-approval changes through lifecycle management. Each update is captured as a new sequence, providing regulators with a clear audit trail.

However, challenges arise when companies:

• Misnumber sequences.
• Submit outdated documents during updates.

To avoid these pitfalls, companies should maintain robust version control systems, clearly track which documents are current, and ensure consistency across all modules. Strong lifecycle management prevents unnecessary resubmissions and supports long-term regulatory compliance.

HSA’s Review Process and Common Queries

Once a dossier passes technical validation, the HSA focuses on scientific and regulatory review. Precision is expected, not only in dossier content but also in how companies respond to deficiency letters.

Best practices include:

• Responding to deficiency letters within the HSA’s stipulated timelines.
• Maintaining an internal log of queries for future submissions.
• Keeping responses concise and referenced, avoiding unnecessary detail.

Requirements by Application Types: Biologics, NCEs, and Generics

While the eCTD framework is standardised, submission requirements differ by application type:

• Biologics licence applications often require additional quality and stability data. They also tend to generate more HSA queries.
• New drug applications typically demand extensive clinical and non-clinical data.
• Generic drug applications usually require bioequivalence studies and reduced content in Modules 4 and 5.

Customisation within the eCTD framework is therefore essential. While the overall structure remains the same, tailoring content to application type ensures compliance and smoother reviews.

Anticipating Future Trends in eCTD Submissions

Globally, regulatory authorities are moving towards eCTD v4.0, which promises greater interoperability across regions. 

In Singapore, the HSA is steadily advancing its digital capabilities. The agency has announced that its eCTD system will be available for test submissions in Q3/Q4 2025, with the official launch date for actual implementation to be confirmed at a later stage. Additionally, the HSA has clarified that all eCTD submissions must be prepared in alignment with International Council for Harmonisation (ICH) specifications to ensure consistency with global standards.

As such, companies must take a proactive approach. By upgrading software and aligning systems with HSA and ICH standards, you reduce the risk of disruption when the system goes live. Early preparation also positions your company for a smoother adoption of future regional and global initiatives.

Future-Proofing Your Submissions with Smarter Strategies

In Singapore, the eCTD provides pharmaceutical companies with a more efficient and structured route to regulatory approval. However, achieving success depends on more than adopting the format. It requires meticulous technical accuracy, strong regulatory expertise, and disciplined lifecycle management.

This is where The Reg Consultants (TRC) can make a difference. Our team provides end-to-end support, from compiling and validating dossiers to managing lifecycle updates in line with HSA requirements. We help companies minimise risks, streamline submissions, and stay ahead of evolving eCTD standards.

Have any questions or want to learn more? Get in touch with us today.

Key Takeaways

• Harmonisation with the ASEAN Common Technical Dossier (ACTD) helps standardise formats, but local variations still exist.
• Different pharmaceutical markets in ASEAN have different review timelines. Strategic sequencing matters.
• A centralised approach strengthens efficiency, especially for multi-country pharma dossier management.
• Experienced partners offering regulatory and advisory services are vital for long-term compliance.

Why Harmonisation Matters Now

The ASEAN pharmaceutical market is one of the fastest-growing globally, offering strong potential for companies that can expand efficiently. Yet, without a harmonised regulatory strategy, firms often face costly delays, repeated work, and regulatory hurdles. Moreover, each country has its own processes, and adapting separately to them can stretch timelines into years.

This is why a well-planned approach using the ACTD framework is essential. By aligning submissions from the outset, pharmaceutical companies can avoid repetitive work, streamline approvals, and secure a stronger competitive position in the region.

What is the ASEAN Common Technical Dossier (ACTD)?

The ACTD was developed to simplify submissions across the region by providing a unified format for regulatory filings. While it draws inspiration from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the ACTD is streamlined and adapted for ASEAN markets.

The ACTD consists of four parts:

• Part I: Administrative and Product Information
• Part II: Quality
• Part III: Nonclinical
• Part IV: Clinical

By aligning submissions with ACTD, companies can prepare a single master file and adapt only the necessary sections to meet local requirements. This not only reduces effort but also ensures greater consistency across regional filings.

What are the Challenges in Local Variations?

Despite the adoption of the ACTD framework, individual ASEAN pharmaceutical authorities continue to enforce their own requirements. These local variations can complicate the submission process and, if not addressed early, cause significant delays. For example:

• Indonesia: According to the National Agency of Drug and Food Control (NADFC), all label information must be written in Bahasa Indonesia. Exceptions include export-only products and specific cases.
• Thailand: Any pharmaceutical product, whether manufactured domestically, imported, or ordered in, must comply with Thailand’s Drug Act B.E. 2510 (1967) and its subsequent amendments.

These country-specific requirements can add months to the process if not planned for early. Engaging pharma regulatory services that recognise these local nuances can help your submissions move forward without avoidable setbacks.

Discrepancies in Timelines and Review Processes

Pharmaceutical approval timelines may also vary widely across ASEAN countries:

• Singapore: The Health Sciences Authority (HSA) outlines timelines of around 12–15 months for a full new drug application.
• Malaysia: According to NPRA guidelines, generic applications generally take about 12–18 months for evaluation.
• Indonesia: Drug registration can range from 12 to 24 months, with biologics often on the longer end.

These differences directly impact resource planning and manufacturing schedules. Strategic sequencing of submissions becomes essential, enabling companies to avoid bottlenecks and better optimise internal teams.

Role of Local Agents and Representatives

Most ASEAN countries require pharmaceutical companies to appoint an in-country representative to manage submissions and post-approval responsibilities. These agents handle regulator queries, coordinate inspections, and oversee pharmacovigilance.

Choosing the right partner is critical. A knowledgeable consultant not only ensures compliance with guidelines but also understands local nuances. In Singapore, for example, pharmaceutical companies should engage experts for HSA registration and regulatory support, preventing costly delays and streamlining the approval process.

What are the Benefits of Centralised Dossier Management?

Centralised dossier management allows companies to maintain a single master file structured around ACTD guidelines, updating only the sections required to meet local variations. This approach not only streamlines preparation but also improves regulatory consistency across the region. 

Key benefits include:

• Efficiency: Reduces duplication of work by creating one master dossier for adaptation.
• Consistency: Minimises discrepancies across harmonised pharma submissions in different ASEAN markets.
• Lifecycle Management: Simplifies renewals, post-approval variations, and safety updates across multiple jurisdictions simultaneously.

This helps align resources with varying review timelines and regulatory expectations, reducing both costs and compliance risks.

Recent and Upcoming Developments in ASEAN

In recent years, the ASEAN Pharmaceutical Product Working Group has intensified its efforts to bring greater alignment across member states. Ongoing initiatives include updates to ACTD standards, harmonisation of stability testing standards, and closer coordination of review requirements. While these changes help reduce discrepancies, companies must stay alert to avoid compliance gaps.

At The Reg Consultants (TRC), our team of regulatory affairs consultants actively monitors these developments, enabling clients to adapt quickly and stay ahead of changes across ASEAN markets.

Conclusion

Harmonising your pharmaceutical submissions across ASEAN countries has become a strategic advantage. By staying aligned with ACTD regulations and anticipating local variations, companies can shorten approval timelines, reduce costs, and streamline regional launches. 

At The Reg Consultants, we specialise in helping companies navigate these complexities. From dossier preparation to in-country support, our team is here to ensure that your strategy is both compliant and efficient. Work with our experts to accelerate approvals and secure lasting success across the region.

Contact us to learn how we can support your next submission.

Key Takeaways

• Module 3 of the Common Technical Document (CTD) tends to be the most scrutinised section in a biologics licence application.
• Incomplete chemistry, manufacturing, and controls (CMC) data, inconsistent speculations, and a lack of scientific justifications are the top reasons behind queries from Health Sciences Authority (HSA).
• Working with an experienced regulatory affairs consultant can help ensure Module 3 is complete, consistent, and fully aligned with HSA expectations.

 

What Is a Biologics License Application (BLA)?

A biologics license application is the formal submission required for the approval of biological products before they can be marketed. In Singapore and many other jurisdictions, this forms a key part of the broader biologics regulatory submission, where authorities assess whether a product meets established standards for quality, safety, and efficacy.

Biologics differ from small-molecule drugs in that they are derived from living systems and involve complex manufacturing processes. As a result, the application places significant emphasis on consistency, process control, and detailed characterisation to support biologics regulatory approval.

At the core of this submission is the Common Technical Document (CTD), a globally harmonised format used to organise regulatory information. It consists of five modules, with Module 3 dedicated specifically to quality data. This module contains the full set of biologics CMC data, covering areas such as manufacturing processes, control strategies, specifications, and stability studies.

Module 3 is particularly critical because it demonstrates how the product is consistently produced and controlled. Any gaps or inconsistencies in this section can delay the biologics registration process or lead to additional queries from regulators. A well-prepared Module 3 therefore forms the backbone of a complete biologics regulatory dossier, supporting both initial submission and long-term lifecycle management.

Key Components of a Biologics License Application

A biologics license application follows the Common Technical Document (CTD) structure, which organises the biologics regulatory dossier into five distinct modules. Each module plays a specific role in supporting the overall biologics regulatory submission, ensuring that regulators have a complete view of the product’s quality, safety, and efficacy.

Module 1 – Administrative Information

This module contains region-specific administrative details required for submission. It typically includes application forms, prescribing information, labelling, and legal documents such as authorisations and certifications. While it does not contain scientific data, inaccuracies here can delay the biologics registration process.

Module 2 – Summaries

Module 2 provides high-level overviews and summaries of the detailed information found in Modules 3 to 5. It includes quality summaries, nonclinical overviews, and clinical summaries, helping regulators quickly understand key aspects of the product. Clear and well-structured summaries support a smoother path towards biologics regulatory approval.

Module 3 – Chemistry, Manufacturing, and Controls (CMC)

This is one of the most critical sections of the application. It contains comprehensive biologics CMC data, including details on manufacturing processes, control strategies, specifications, and stability. Given the complexity of biologics, this module plays a central role in demonstrating product consistency and quality throughout the biologics regulatory submission.

Module 4 – Nonclinical Data

Module 4 includes results from laboratory and animal studies that evaluate the product’s pharmacology and toxicology. These studies provide early evidence of safety and biological activity, forming an essential foundation before progressing to human trials.

Module 5 – Clinical Data

This module contains clinical trial data that demonstrate the product’s safety and efficacy in humans. It includes study reports, protocols, and statistical analyses, all of which are critical for securing biologics regulatory approval. Together with the other modules, it completes the evidence required for a successful submission.

Why Module 3 Is Critical in a Biologics License Application

Within a biologics license application, Module 3 plays a central role in demonstrating product quality and control. As biologics are derived from living systems, even small variations in manufacturing can affect the final product. This makes the quality section a key focus area in any biologics regulatory submission, often determining whether the application progresses smoothly towards biologics regulatory approval.

Manufacturing complexity is one of the main reasons Module 3 carries such weight. Unlike small-molecule drugs, biologics involve multi-step processes such as cell culture, purification, and formulation. Each step must be clearly defined and controlled, with sufficient detail provided in the biologics CMC data to show reproducibility and reliability.

Batch consistency is another critical consideration. Regulators expect evidence that the product can be manufactured consistently across different batches, with minimal variability. This includes validated processes, in-process controls, and defined acceptance criteria that support a stable and predictable outcome throughout the biologics registration process.

Analytical validation further strengthens the submission by demonstrating that testing methods are suitable for their intended purpose. Methods used to assess identity, potency, purity, and impurities must be validated to ensure accurate and reliable results, forming a key component of the overall biologics regulatory dossier.

Stability studies complete the picture by showing how the product maintains its quality over time under various storage conditions. These studies support shelf-life claims and provide assurance that the product remains safe and effective throughout its lifecycle. Any gaps or inconsistencies in this area may lead to additional queries or delays during review.

Taken together, Module 3 serves as the backbone of the submission, linking manufacturing, testing, and long-term product performance into a cohesive and well-supported dataset.

Module 3: A Common Roadblock in Biologics Submissions

In biologics submission in Singapore, Module 3 of the CTD is a critical component. It addresses CMC and ensures biologics are consistently produced to meet stringent quality, safety, and efficacy standards. For submissions made by brands or regulatory representatives in Singapore, the HSA pays particular attention to this module, and errors can result in prolonged queries or outright rejections.

Given the complexity of biologics, regional regulatory differences, and the need for robust data packages, working closely with a regulatory affairs consultant from the early stages can streamline compilation and prevent late-stage surprises.

Module 3 (CMC) data needs to demonstrate that the biologic is consistently manufactured, controlled, and characterised to meet quality, safety, and efficacy standards. Regulatory authorities like HSA, EMA, and FDA expect comprehensive, well-justified data covering:

• Drug substance characterisation: Physicochemical properties, biological activity, glycosylation profiles, impurities, and batch consistency (ICH Q5A/B/C, aligned with FDA biologics license application requirements)
• Drug product controls: Formulation, container closure systems, in-process controls, and batch-to-batch consistency.
• Stability programs: Real-time and accelerated studies demonstrating product quality across shelf-life.
• Analytical methods and validation: Accurate, precise, and suitable for intended use.

Failing to meet these expectations can trigger major HSA queries, which often mirror FDA/EMA review concerns, including incomplete justification for specifications or missing comparability data.

1. Incomplete CMC Information

Incomplete CMC data is one of the top causes of major HSA queries. This may include:

• Missing process flow diagrams or incomplete control strategy descriptions
• Fragmented batch analysis data or inconsistent release specifications
• Lack of raw material characterisation for critical components

Mitigation strategy:

• Integrate multi-site manufacturing data early and reconcile inconsistencies
• Map critical quality attributes (CQAs) to control strategies (per ICH Q8/Q9/Q10)
• Conduct internal pre-submission audits to identify gaps before HSA review

To avoid this, implement a Module 3-specific checklist and involve CMC, quality assurance (QA), and regulatory teams early in the development process. Tracking data readiness from the outset ensures that your biologics licence application progresses smoothly without unexpected information gaps.

2. Cross-Section Inconsistencies

Inconsistent data is a common source of concern for HSA reviewers and can quickly undermine the integrity of a submission. Examples include:

• Mismatched drug substance and drug product specifications
• Contradictory analytical results
• Mislabelled manufacturing sites

Such discrepancies erode credibility, trigger major queries, and can lead to significant delays in approval. To mitigate these risks, companies and marketing authorisation holders should:

• Implement cross-functional verification and formal data reconciliation before submission
• Maintain version-controlled master documents to ensure accuracy across all sections
• Work closely with an in-country regulatory rep or a regulatory affairs (RA) consultant for product approval in Singapore. This ensures rigorous cross-checking and alignment.

This ensures rigorous cross-checking, alignment with HSA requirements, and fewer post-submission queries

3. Failure to Justify Specifications

Regulators expect every specification in Module 3 to be backed by a clear scientific rationale, as outlined in ICH Q6B. However, many submissions fail to meet this requirement by presenting specifications without linking them to reference standards, stability data, or risk-based controls.

To address this, companies should:

• Reference recognised pharmacopeial standards where applicable
• Connect specifications to manufacturing controls and stability study outcomes
• Document the rationale in a structured justification report to demonstrate compliance and data integrity.

Providing this level of scientific justification ensures that your biological licence application proceeds smoothly and shows reviewers that your company takes quality seriously. By partnering with The Reg Consultants (TRC), an experienced provider of pharma regulatory services, you gain the expertise and guidance needed to meet expectations with confidence.

4. Non-Compliant Stability Data

For biologics, HSA reviewers expect a robust stability package, including:

Multiple timepoints, stress conditions, and representative batches

Comparability studies after manufacturing changes, site transfers, or scale-up

Demonstrated link between stability data and shelf-life claims

These gaps increase the likelihood of HSA queries and delays. To mitigate risks, stability programmes should be designed from the outset with both ICH and ASEAN frameworks in mind, supported by validated analytical methods. Submissions must also include both real-time and accelerated data to provide a complete and compliant evidence package.

5. Poor Quality Translation and Formatting

Even when the underlying science is sound, poor presentation can compromise the credibility of a submission. Reviewers frequently encounter issues such as:

• Sloppy translations
• Missing headers
• Inconsistent numbering
• Misaligned tables
• Incomplete legends

These shortcomings can frustrate HSA reviewers and extend the timelines for your biologics licence application. To avoid such setbacks, companies should engage professional regulatory translators, adopt CTD-compliant templates, and conduct thorough quality control reviews before submission. Attention to detail in presentation not only reflects data integrity but also reinforces overall professionalism.

Strengthen Your Module 3 with Expert Support

Module 3 remains one of the most critical components of a biologics licence application, and it is also where many submissions face avoidable delays. By addressing critical gaps and ensuring internal consistency, companies can significantly reduce the risk of major queries.

At The Reg Consultants (TRC), we act as your regulatory affairs consultant and provide comprehensive HSA registration and regulatory support in Singapore, ensuring your Module 3 is accurate, complete, and inspection-ready. Our team facilitates smooth communication with HSA, enabling quicker resolution of queries and faster time to approval.

Connect with The Reg Consultants today to strengthen your Module 3 and improve your submission success rate.

FAQs on Biologics License Applications

What data is required for a biologics license application?

A biologics license application requires comprehensive data covering quality, safety, and efficacy. This includes detailed CMC information, nonclinical study results, and clinical trial data. In particular, the quality section must demonstrate consistent manufacturing processes, validated analytical methods, and stability data to support shelf life.

What is included in CTD Module 3 for biologics?

CTD Module 3 contains the Chemistry, Manufacturing, and Controls (CMC) section. It includes information on drug substance and drug product manufacturing, control strategies, specifications, analytical validation, and stability studies. This module forms a key part of the overall regulatory dossier and is often the focus of regulatory review.

Why do biologics license applications face regulatory queries?

Regulatory queries often arise due to gaps or inconsistencies in data, particularly within Module 3. Common issues include incomplete characterisation, insufficient validation of analytical methods, or lack of comparability data. Addressing these areas early with the support of a regulatory affairs consultant can help reduce the likelihood of delays.

How long does a biologics license application review take?

The review timeline can vary depending on the regulatory pathway, completeness of the submission, and the number of queries raised during evaluation. In Singapore, timelines are influenced by HSA’s review process and whether the submission relies on prior approvals from reference agencies.

How much does it cost to submit a BLA?

Costs can vary widely depending on the complexity of the product, the scope of required studies, and regulatory fees. Additional costs may arise from addressing queries or conducting supplementary studies. Engaging pharma regulatory services early in the process can help optimise resources and avoid unnecessary rework.

For companies navigating complex submissions, having access to HSA registration and regulatory support in Singapore can make a meaningful difference in ensuring compliance and reducing delays. If you need tailored guidance for your submission, please contact us for further assistance.

Key Takeaways

• Health Sciences Authority (HSA) pre-submission meeting ensures that companies clarify data expectations and regulatory requirements. 
• Early clarification with HSA can minimise costly delays due to non acceptance of bridging data, inadequate demonstration of efficacy studies to claimed indications
• Preparing clear briefing documents, agendas, and supporting data ensures productive discussions.
• The Reg Consultants provides pharma regulatory services to help clients navigate HSA guidelines with confidence.

Why Pre-Submission Meetings Are a Strategic Advantage

For companies planning a new drug application or biologic submission in Singapore, the pre-submission meeting with Health Sciences Authority (HSA) can be a critical step especially if your product is a novel therapeutic product and developed in the absence of, or deviates from local or international regulatory guidance. This meeting allows applicants to align on data expectations, clarify regulatory requirements, and proactively address potential gaps—significantly reducing the risk of delays or additional queries.

At The Reg Consultants (TRC), we guide clients through every stage of the process, from preparing the right documents to rehearsing answers for HSA’s most likely questions. Here’s what you can expect from the process and how to prepare effectively.

What is a HSA Pre-Submission Meeting, and When is it Needed?

A HSA pre-submission consultation is recommended for new chemical entities (NCEs), biologics, biosimilars, and other complex therapeutic products which has never been approved anywhere else in the world or has new approaches to the development of the drug which might imapact on the safety and quality which they need consultation on . It is typically scheduled before submitting a new drug application or major variation.

During this session, you can present clinical data, manufacturing details, and proposed indications directly to HSA reviewers. Addressing these questions early will help you and your company avoid major data misalignments or gaps that often result in prolonged review cycles. In fact, having clear discussions with HSA upfront can save three to six months on overall submission timelines, giving your product a faster path to approval.

Required Documents for the Meeting

To maximise the value of the pre-submission meeting, it is important to provide clear, well-organised documents. These include:

• Proposed agenda for the meeting;
• Summary information which may include Chemistry, Manufacturing and Controls (CMC)/ non-clinical/ clinical information of the product and proposed application;
• Specific scientific issues that require advice

Preparing these materials ahead of time and aligning with guidelines ensures that the HSA has all the necessary information, allowing them to provide meaningful feedback.

Common HSA Questions for NCE and Biologic Submissions

During pre-submission meetings, HSA reviewers often raise questions that test both scientific and regulatory readiness. Here are some of the areas they may focus on:

• The design of clinical trials and whether the selected endpoints are appropriate.
• Comparability data and evidence supporting biosimilars.
• The justification for proposed indications, dosage, and target patient population.
• Manufacturing processes, quality controls, and overall assurance of product consistency.
• Plans for post-market surveillance and risk management.

Since these questions often require detailed and well-supported answers, having a trusted regulatory affairs consultant by your side can make a critical difference. TRC offers tailored mock Q&A sessions to help technical and regulatory teams practise their responses. This proactive approach ensures your team is well-prepared to engage with reviewers, demonstrate compliance, and address even the most challenging queries.

How TRC Prepares Clients for Successful Meetings

At The Reg Consultants, our role goes beyond document preparation, providing comprehensive regulatory support and guidance tailored to each client’s needs. This includes:

• Gap assessments to evaluate dossier readiness before engaging HSA.
• Drafting briefing documents that anticipate regulatory concerns.
• Running mock Q&A rehearsals to strengthen the preparedness of your technical team.
• Advising on meeting strategies, including how to present risk areas and mitigation measures.
• Documenting agreements made during the meeting to avoid disputes later in the approval process.

Through this structured approach, we empower clients to approach HSA pre-submission meetings with confidence, all while ensuring that outcomes are clear and actionable. 

Why HSA Guidance Matters for NCE and Biologics

A HSA pre-submission meeting should be viewed not as a procedural step but as a strategic opportunity. Key benefits include:

• Reduced risk of delays, additional data requests, or outright rejection.
• Early alignment with HSA guidelines, which reduces uncertainty over evidence thresholds.
• Greater clarity on regulatory expectations.

For companies submitting a biologics licence application or new drug dossier, pre-submission meetings are invaluable in accelerating time-to-market and building trust with regulators.

Preparing for Approval with Guidance You Can Trust

A HSA pre-submission meeting is more than a formality. Rather, it’s a valuable opportunity to strengthen your regulatory submissions, anticipate authority concerns, and accelerate approval timelines. With TRC’s proven expertise in HSA registration and regulatory support in Singapore, we can help your team approach these meetings fully prepared, confident, and aligned with HSA guidelines. 

Partner with us today to set your submission on the right path from the start.

Key Takeaways

• Singapore provides a robust regulatory framework that supports regional expansion.
• Participation in ASEAN mutual recognition arrangements (MRAs) accelerates product approvals.
• Efficient licensing processes reduce time-to-market compared to other jurisdictions.
• A centralised Singapore base can coordinate regional product launch strategies.
• Access to skilled professionals and regulatory consultants strengthens compliance planning.

Singapore as a Strategic Base for ASEAN Regulations and Market Expansion

For pharmaceutical and life science companies , Singapore has become a strategic launchpad into Southeast Asia. Its well-established regulatory system, supported by Health Sciences Authority (HSA), gives organisations confidence when planning entry into multiple ASEAN markets. HSA’s framework is aligned with international guidelines such as ICH guidelines which forms as the base for reference in ASEAN, ensuring that data submitted in Singapore can often be leveraged for ASEAN CTD (ACTD) dossiers across the region. Combined with regional trade frameworks and mutual recognition initiatives, Singapore offers an effective pathway for businesses seeking to align with ASEAN regulations while preparing for wider market distribution.

Several regulatory and strategic factors reinforce Singapore’s role as a launchpad for companies seeking access to ASEAN markets. The following five considerations are particularly relevant.

Robust Regulatory Framework

Singapore’s regulatory approach is recognised for its alignment with international benchmarks. HSA adopts standards that mirror global best practices, ensuring regulatory outcomes that are trusted across borders. For companies seeking Singapore pharmaceutical registration, this foundation provides assurance that dossiers and processes will be viewed as credible when approaching neighbouring markets. Establishing compliance here first can help streamline engagement with other regulators across ASEAN, many of whom refer to or respect Singapore’s regulatory decisions. A common pitfall is underestimating the level of CMC data harmonisation required across ASEAN such as ZoneIVb studies ; aligning with HSA standards first can help address data gaps before engaging other regulators.

Mutual Recognition Arrangements (MRAs)

While ASEAN has taken steps toward regulatory harmonisation, true mutual recognition for pharmaceuticals remains limited. Unlike medical devices, there is no automatic acceptance of drug approvals across ASEAN markets. Instead, companies can leverage Singapore’s ICH-aligned standards and HSA’s credibility to strengthen ASEAN CTD (ACTD) dossiers and reduce repetitive queries. In practice, positioning Singapore as the first point of submission often helps anticipate data gaps (e.g., stability, CMC) before engaging with other ASEAN authorities.

Engaging a regulatory affairs consultant at this stage can help companies interpret how Singapore’s framework aligns with international standards and how this alignment can support wider ASEAN submissions.

Efficient Licensing Process

Singapore’s regulatory pathways are relatively transparent, with clear timelines and published guidance. The verification route, for example, can significantly shorten approval timelines where prior reference agency approval (e.g., US FDA, EMA) has been obtained . Common pitfalls include underestimating Module 3 data requirements or submitting incomplete stability information. Addressing these points early allows companies to establish a stronger baseline in Singapore, then manage staggered ASEAN submissions more efficiently.

Centralised Operations with Regional Reach

Singapore is frequently used as a regional coordination hub for regulatory submissions. Centralising dossier management here helps companies maintain consistency across multiple ASEAN markets, particularly when managing lifecycle variations such as manufacturing changes or new indications. Having one “master” dossier anchored in Singapore reduces discrepancies and ensures updates can be rolled out more efficiently across the region.

Talent Pool and Regulatory Consultants

Singapore also offers access to a strong base of experienced professionals in regulatory affairs. This includes both in-house specialists and external support from firms providing pharma regulatory services. Engaging a skilled regulatory affairs consultant is often key to navigating the complexities of differing ASEAN frameworks. Their expertise ensures that submissions and compliance strategies are tailored to each market, while maintaining the efficiency of a centralised approach anchored in Singapore.

Maximising Opportunities Through Singapore

Singapore provides pharmaceutical and life sciences companies with a clear regulatory pathway into ASEAN. Its alignment with international standards, participation in MRAs, and efficient licensing processes offer a foundation for compliance and market access. Combined with its role as a regional hub and access to regulatory expertise, Singapore represents a pragmatic choice for businesses planning ASEAN expansion.

Companies planning ASEAN submissions can benefit from early regulatory strategy discussions to streamline multi-country approvals. The Reg Consultants supports clients with end-to-end planning for Singapore registration and regional market entry — connect with The Reg Consultants to explore your regulatory strategy.

We’re back for our weekly deep dive into the fascinating world of regulatory affairs! This week, I want to tackle a topic that comes up surprisingly often in my conversations with clients, especially those looking to bring life-saving products like vaccines to new markets: How do you leverage a WHO Prequalified (PQ) dossier for registration in Singapore?

Many assume a WHO PQ means a straight shot, but as we as seasoned regulatory people know, it’s rarely that simple. While WHO Prequalification is an incredible achievement and a powerful foundation, there are always those crucial local nuances that need expert navigation.

What Exactly is a WHO Prequalified Dossier?

The World Health Organization (WHO) Prequalification program is a global initiative designed to ensure that key health products meet international standards of quality, safety, and efficacy. Think of it as a stamp of global assurance. WHO conducts a rigorous assessment, scrutinizing everything from the product’s quality data to the manufacturing site’s Good Manufacturing Practice (GMP) compliance. It’s a comprehensive review aimed at facilitating access to essential, quality-assured medical products, particularly for procurement by UN agencies and other international bodies.

What Kinds of Products Fall Under WHO PQ?

Initially, the program focused heavily on medicines for HIV/AIDS, TB, and malaria. Over time, it has expanded significantly. Today, WHO Prequalification covers a broad spectrum of products vital for global health, including:

• Medicines (Finished Pharmaceutical Products and Active Pharmaceutical Ingredients): Especially generics and essential medicines.
• Vaccines: This is a huge one! Ensuring vaccine quality and efficacy for global immunization programs is a cornerstone of WHO PQ.
• In Vitro Diagnostics (IVDs): Products used for detecting diseases.
• Immunization Devices: Like syringes and safety boxes.
• Vector Control Products: Tools to fight vector-borne diseases.

Based on experiences and inquiries, vaccines are often the first product that comes to mind when leveraging WHO PQ. The principles, however, apply broadly across these categories.

Advantages of a WHO PQ Dossier

The advantages are:

• A Global Seal of Quality: A WHO PQ product has already undergone a thorough evaluation by a globally respected authority. This immediately instills confidence in national regulatory agencies (NRAs) about the product’s quality, safety, and efficacy profile.
• Streamlined Initial Review: For many NRAs, especially those with limited resources, a WHO PQ can significantly streamline their initial assessment, as much of the heavy lifting on the core scientific data has already been done.
• Market Access and Procurement: For many manufacturers, WHO PQ is a prerequisite for supplying products to major international procurement bodies, opening up vast markets.
• Robust Scientific and Quality Foundation: The WHO Prequalified dossier provides a comprehensive, pre-vetted scientific and quality package (often in CTD format). This means the core technical data, which is typically the most time-consuming to generate and compile, is largely established, significantly reducing the burden of its “major overhaul” when preparing for national submissions.

Bridging the Gap for Singapore Submission

Here are the key gaps we typically need to bridge:

• Local Administrative & Legal Requirements (Module 1): The WHO PQ dossier, while often following the CTD structure, will have a WHO-specific Module 1. HSA, like any national authority, has its own unique Module 1 requirements. This includes specific application forms, declarations, appointment of a local company/agent (which, surprise, surprise, is a must!), and adherence to local legal frameworks.
• Singapore-Specific Labelling & Package Inserts: Even if the core data is accepted, the product information (labels, package inserts, patient information leaflets) must be fully compliant with HSA’s detailed requirements for language, content, and format. This isn’t just a translation job; it’s a regulatory art form!
• Good Manufacturing Practice (GMP) Conformity: While WHO conducts GMP inspections for PQ, HSA recognizes PIC/S GMP as the standard. Based on recognition agreements and internal evaluation, manufacturing sites can either be subjected to a GMP DEVA assessment or an overseas inspection.
• Risk Management Plan (RMP): HSA requires a comprehensive Risk Management Plan, along with a Singapore-Specific Annex (SSA), to be submitted as part of the registration application for therapeutic products, including vaccines.
• Vaccine-Specific Lot Release: This is a crucial point for vaccines! Even after registration, all imported registered vaccines require a notification to HSA on lot release information before they can be supplied in Singapore. This is a critical post-registration compliance step.
• Dossier Format Alignment (ICH CTD/ACTD): While WHO PQ is increasingly aligned with CTD, HSA accepts both ICH CTD and ASEAN Common Technical Dossier (ACTD) formats. There can be subtle but important differences in how information is presented or what specific details are required within certain sections, especially if the ACTD format is chosen or if there are specific HSA guidance documents that refine the CTD expectations.

Essentially, a WHO PQ dossier gives you a solid scientific and quality foundation in which “a major overhaul” is essentially avoided when preparing for local submission.

How TRC Can Support Your Journey

TRC specializes in taking WHO Prequalified dossier and meticulously transforming it into a complete, compliant submission for HSA.

We don’t just translate documents; we understand the intent behind HSA’s guidelines and the specific nuances of what they’re looking for. From managing the intricate Module 1 administrative requirements, ensuring all labelling is compliant, to advising on GMP assessments and navigating the vaccine-specific lot release process – we cover all the bases.

Our “on-the-ground” practical experience in Singapore regulatory affairs means we can foresee potential roadblocks and proactively address them, streamlining your path to market. We work like an extension of your own team, guiding you through every step, ensuring that your life-saving vaccines, or any other WHO Prequalified product, reach the patients who need them, right here in Singapore.

Ready to make your WHO PQ a launchpad for Singapore market access?

A structured regulatory strategy is critical to ensure successful submission and lifecycle management. You may refer to our pharmaceutical regulatory support services for further details.

Amongst the ever-emerging trend of new generation drugs, there is a group that is not widely discussed yet still remains the gold standard of treatment — or even serves as the pharmacophore on which many modern drugs are built. Examples of grandfather products include aspirin, morphine, diphenhydramine, and propranolol — all introduced decades ago and still widely used today. Their pharmacophore structures have inspired the development of many modern drugs, demonstrating the enduring value of these legacy products. This term is exchanged quite regularly during conversations here and there but is often neglected when strategizing market entry. Today, we are here to touch on this group of special products.

What are Grandfather or Legacy Products?

In regulatory terms, grandfather products (also called legacy products) refer to products that were introduced to the market before modern regulatory frameworks were established. For chemical entity drugs, this usually means they were first approved decades ago under older requirements and have remained on the market with minimal updates to their dossiers.

Where do grandfather products often originate from?

Most grandfather or legacy products originate from established pharmaceutical markets such as the United States, Europe, and Japan, where products were approved under national regulations before harmonized ICH guidelines existed. Additionally, some products from regional manufacturers in ASEAN or other Asia-Pacific countries also fall into this category if they were registered locally before CTD implementation.

Such products may:

• Lack comprehensive ICH CTD-format dossiers, making it difficult to directly submit to regulatory authorities that require standardised formats
• Be registered under older country-specific formats with missing modules (e.g. no full Module 3 CMC data and incomplete Module 5 clinical data), resulting in significant rework before submission
• Have undergone manufacturing or formulation changes over time not fully captured in the current registration file, raising concerns on data consistency, bridging justifications, and regulatory acceptability

 

Common Issues with Legacy Product Dossiers

From my experience, clients often face these challenges with grandfather chemical entity products:

• Missing Module 3 data :Older products may only have a brief manufacturing summary without detailed process validation, impurity profiles, or stability data as per current ICH/ASEAN requirements. This leads to delays in submission preparation as sourcing and compiling such data can take months or require additional manufacturer support.
• Non-compliance with current guidelines:
  Specifications, analytical methods, and validation reports may not align with updated pharmacopeial or ICH standards. This could result in deficiency queries or rejection if no bridging justification is provided. – Specifications, analytical methods, and validation reports may not align with updated pharmacopeia or ICH standards.
• Outdated safety or clinical information : For most well-established grandfather products, additional clinical data is generally not required if the product retains its original formulation, indication, and dosage form, and has a long history of safe use. However, dossiers may still lack current risk management plans or pharmacovigilance documentation, which are standard expectations under modern regulatory frameworks. In some cases, if a product is being introduced in a new dosage form or combined with a novel formulation, regulators may request bridging data or justification to confirm its safety and efficacy in the proposed context.

How TRC Can Help

At TRC, we support clients to resolve these gaps for market entry or re-registration in Singapore. Here are realistic examples of solutions we have provided:

Case 1: CMC Gap Analysis and Strategic Planning

A client approached us to register a 1980s-origin chemical entity analgesic in Singapore. The original dossier had:

• No detailed process validation reports

• Only finished product specifications with limited analytical validation data

Our approach:

1. Conducted a Module 3 gap analysis against HSA’s current requirements
2. Identified critical missing data and advised on the feasibility of sourcing them from the manufacturer or via new testing
3. Developed a regulatory strategy to allow the client to decide whether to proceed with registration or prioritise alternative products in their portfolio

Case 2: Regulatory Intelligence Assessment for antibiotic 

A Southeast Asian client aimed to bring in a legacy antibiotic product registered regionally before ASEAN CTD implementation.

Our approach:

1. Conducted a regulatory intelligence assessment to clarify HSA expectations for legacy products
2. Identified potential data requirements (e.g. stability data under ASEAN climatic zone IVb conditions, updated impurity profile data)
3.  Prepared a clear requirements list for the client to initiate discussions with their manufacturer efficiently and to plan next steps for dossier preparation

Case 3: Specification and Analytical Review Support for CNS Product

A European manufacturer sought to register a CNS (central nervous system) drug but its finished product specifications were outdated.

1. Reviewed the current USP/EP standards for the active ingredient and finished product
2. Provided recommendations to align the specifications with current standards to mitigate the risk of questions being raised during screening and evaluation
3. Guided the client in preparing bridging justification documents to support acceptance of older analytical methods with supplementary validation where needed

Legacy or grandfather products hold strong market value, but their outdated dossiers often pose barriers to registration under modern frameworks.

Performing a regulatory intelligence exercise early — to understand current requirements and feasible pathways — is critical. Starting a gap analysis as the first step ensures that data gaps can be proactively addressed, reducing time to market entry.

At TRC, we specialise in guiding clients through these complexities to achieve successful registration outcomes in Singapore. Contact us if you need support in revitalising your legacy products for new market opportunities.

We often get leads from prospects telling us:

“My product is FDA/EMA approved, so there shouldn’t be any issue for local submission. Efforts on your end should be minimal – can we reduce costs?”

I’m sure those who know the reality are quietly laughing behind their screens as I say this.

Why Do We Still Need Local Preparation?

When preparing a regulatory submission, having reference agency approval:

• Supports your application, as the dossier has been reviewed by a stringent authority

• Provides assessment reports that local health authorities can leverage to evaluate safety, quality, and efficacy

But here is the reality: reference agency dossiers are not fully representative of local requirements. Regulations are built upon international standards and incorporate specific national requirements, dossier formats, and administrative expectations that local marketing authorization holders should adhere to.

While reliance pathways and reference agency approvals can facilitate regulatory decision-making, they do not eliminate the need for a localised assessment of quality, safety, and efficacy.

Critical Gaps We Often See

1. Generics: Local bioequivalence (BE) requirements, acceptance of foreign BE studies, and strict reference product criteria can differ greatly from those in the US or EU.

2. Biosimilars: Local authorities may request additional analytical data or bridging studies when the reference biologic is sourced differently.

3. NCEs: While clinical data may be robust globally, gaps can occur if local clinical pharmacology factors—such as food effects, drug interactions, or special population data—are insufficient or missing.

4. Stability studies not performed in accordance with Zone IVb requirements.

5. Process validation performed but lacking validation data for all commercial-scale batches (only pilot scale provided), absence of hold time validation data for in-process materials or bulk product, or no justification for process parameter ranges or their linkage to critical quality attributes (CQAs).

6. Manufacturing controls not clearly demonstrating the linkage between drug substance and finished product manufacturer.

7. GMP standards adopted not aligned with PIC/S requirements.

Other Common Issues We Encounter

• Dossiers submitted not in the required ASEAN CTD or ICH CTD format

• Outdated Quality Overall Summary (QOS) that does not reflect current drug substance (DS) and drug product (DP) changes

• “‘Grandfather” products  registered based on old regulations or legacy processes may still be accepted in reference countries but often fail to meet evolving local regulatory requirements leading to challenges in registration.

What Should You Do?

In many cases, the challenges do not arise from the data itself, but from how the dossier is structured and aligned to local regulatory expectations.

If you want to register your product locally, it is essential to:

1. Conduct regulatory intelligence to understand local requirements and assess your dossier gaps before submission.

2. Engage an external local expert to perform a targeted gap analysis to de-risk your registration process.

How TRC Can Support You

We can help by:

• Identifying missing documents or data

• Adapting dossiers efficiently to local requirements

A structured regulatory strategy is critical to ensure successful submission and lifecycle management. You may refer to our pharmaceutical regulatory support services for further details.